



1 July 2021

ReNeuron Group plc
("ReNeuron" or the "Company")

Directorate Change

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces today that Iain Ross has joined as a Non-Executive Director and Chairman of the Board of Directors with immediate effect. Dr. Tim Corn is stepping down as Chairman of the Board of Directors, but will remain as a Non-Executive Director.

Iain Ross is a highly experienced board director with a career in the international life sciences and technology sectors that spans 40 years. He held senior commercial roles at Sandoz, Fisons and Hoffman La Roche before moving into the biotechnology sector where he has been Chairman, CEO and Director of several international biotechnology companies including Celltech Group plc, Quadrant Healthcare plc and Redx Pharma plc.

Currently he is Non-Executive Chairman at Silence Therapeutics PLC (LSE/NASDAQ) and Kazia Therapeutics Limited (ASX/NASDAQ). Mr Ross is a qualified Chartered Director, Fellow of the Institute of Directors and Honorary Fellow of Royal Holloway, London University.

Olav Hellebø, Chief Executive Officer of ReNeuron, commented: *"We are delighted to welcome Iain to the ReNeuron team as Non-Executive Director and Chairman. Iain has considerable experience with commercially successful international lifescience businesses and we welcome his support as we enter into a period where we expect to reach important, data-driven value inflection points across our programmes over the next 12 months."*

Iain Ross, Incoming Chairman of the Board of Directors at ReNeuron, commented: *"I am delighted to be joining ReNeuron at such a pivotal time and look forward to working with the Board & Management and to ensuring a significant uplift in shareholder value over the next few years."*

The following information is disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:
Full name and age: Iain Gladstone Ross (aged 67)

Iain Ross does not currently hold any shares in ReNeuron.

Current Directorships or Partnerships:

- Biomer Technology Limited
- Gladstone Consultancy Partnership
- Gladstone Partners Limited
- Kazia Therapeutics Limited
- Palla Pharma Ltd
- Silence Therapeutics PLC

Previous Directorships or Partnerships:

- Aldershot Town Football Club Limited
- Anantara Life Sciences Ltd
- Benitec Biopharma Limited
- E-Therapeutics plc
- Innopeg Limited
- Pharmed Limited
- Premier Veterinary Group plc
- Redx Immunology Limited
- Redx Oncology Ltd

- Redx Pharma plc
- Redx Anti-Infectives Ltd
- Redx MRSA Limited
- Rosscard Leisure Limited
- Silence Therapeutics (London) Ltd
- Tacere Therapeutics Inc
- Yellowcross Limited

Iain Ross joined the board of Redx Pharma plc on 1 May 2017. On 24 May 2017, Redx Pharma plc and Redx Oncology Ltd were put into administration by Liverpool City Council as a result of non-payment of an outstanding loan of £2m and shares in Redx Pharma plc were suspended. On 3 November 2017 Redx Pharma plc and Redx Oncology Ltd exited administration with all creditors paid and trading in Redx Pharma plc resumed, under the Chairmanship of Iain Ross.

No further information in connection with the appointment of Iain Ross is required to be disclosed under Schedule Two, paragraph (g) of the Aim Rules for Companies.

ENDS

Contacts:

ReNeuron

Olav Hellebø, Chief Executive Officer

www.reneuron.com/investors

Via Walbrook PR

Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)

Ben Maddison, Stewart Wallace

+44 (0)20 7710 7600

Allenby Capital Limited (Joint Broker)

James Reeve/George Payne (Corporate Finance)

Tim Sohal (Sales & Corporate Broking)

+44 (0)20 3328 5656

Walbrook PR (Media & Investor Relations)

Paul McManus, Alice Woodings

+44 (0)20 7933 8780 or reneuron@walbrookpr.com

+44 (0)7980 541 893 / +44 (0)7407 804 654

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments for disease with significant unmet needs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the central nervous system and other disorders. The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make allogeneic tissue cells of choice; in-house programmes are currently focused on treatments for blood cancers and diabetes.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com